Trial Profile
A MultiCentre, Randomized, Double-blind, Placebo-controlled Phase IIb Study to Compare the Efficacy and Safety of Two Dosing Regimens of Intravenous Infusions of AZD9773 (CytoFab™) in Adult Patients With Severe Sepsis and/or Septic Shock
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 06 Nov 2021
Price :
$35
*
At a glance
- Drugs Anti-TNF-alpha polyclonal antibody (Primary)
- Indications Sepsis; Septic shock
- Focus Therapeutic Use
- Sponsors AstraZeneca
- 06 Jun 2014 New trial record